Medlive Technology Co., Ltd. (HK:2192)
:2192
Want to see HK:2192 full AI Analyst Report?
2192 Stock Chart & Stats
HK$9.83
-HK$0.01(-0.11%)
At close: 4:00 PM EST
HK$9.83
-HK$0.01(-0.11%)
Day’s Range― - ―
52-Week RangeHK$6.66 - HK$17.04
Previous CloseN/A
Volume1.04M
Average Volume (3M)1.46M
Market Cap
HK$4.93B
Enterprise ValueHK$1.87B
Total Cash (Recent Filing)HK$3.72B
Total Debt (Recent Filing)HK$10.11M
Price to Earnings (P/E)12.6
Beta1.32
Next Earnings
Sep 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield2.72%
Share Statistics
EPS (TTM)0.45
Shares Outstanding740,114,140
10 Day Avg. Volume901,132
30 Day Avg. Volume1,461,578
Financial Highlights & Ratios
PEG Ratio2.71
Price to Book (P/B)1.32
Price to Sales (P/S)10.00
P/FCF Ratio52.74
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$13.10Price Target Upside33.27% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)0.49
Revenue Forecast (FY)HK$753.08M
Bulls Say, Bears Say
Bulls Say
Balance-sheet ConservatismNear-zero debt materially reduces financial risk and gives management durable flexibility to fund product development, pursue opportunistic M&A or weather industry cycles without refinancing pressure. A conservative balance sheet supports capital allocation consistency over months to years.
High Profitability And MarginsSustained very high gross and net margins indicate strong pricing power and a low-cost operating model, providing a structural cushion against revenue volatility. High margins support reinvestment in platform features, fund shareholder distributions, and improve resilience over a multi-quarter horizon.
Platform Model With Recurring Pharma DemandA physician-facing platform with repeat pharma customers creates recurring revenue, network effects and high switching costs. Over months this structural client base supports predictable campaign demand and cross-sell of education, promotion and platform services, stabilizing top-line potential.
Bears Say
Material 2025 Revenue DeclineA sharp 24% top-line drop in 2025 undermines confidence in growth durability and suggests sensitivity to client spending cycles or contract timing. Such a reversal can persist across multiple quarters, reducing scale benefits and constraining reinvestment and long-term growth momentum.
Weak Cash Conversion And Choppy FCFModest cash conversion means reported earnings do not reliably convert to cash, limiting sustainable funding for capex, acquisitions, or dividends. Choppy free cash flow increases vulnerability to revenue swings and raises the risk that earnings volatility will pressure investment plans over several quarters.
Moderate Returns On Equity Given Low LeverageVery low leverage reduces financial risk but also limits return amplification; a ROE around 6–7% implies modest shareholder returns unless operational efficiency or new growth initiatives lift margins or asset turnover. That constraint can persist absent strategic change.
Medlive Technology Co., Ltd. News
2192 FAQ
What was Medlive Technology Co., Ltd.’s price range in the past 12 months?
Medlive Technology Co., Ltd. lowest stock price was HK$6.66 and its highest was HK$17.04 in the past 12 months.
What is Medlive Technology Co., Ltd.’s market cap?
Medlive Technology Co., Ltd.’s market cap is HK$4.93B.
When is Medlive Technology Co., Ltd.’s upcoming earnings report date?
Medlive Technology Co., Ltd.’s upcoming earnings report date is Sep 01, 2026 which is in 71 days.
How were Medlive Technology Co., Ltd.’s earnings last quarter?
Medlive Technology Co., Ltd. released its earnings results on Mar 26, 2026. The company reported HK$0.267 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.267.
Is Medlive Technology Co., Ltd. overvalued?
According to Wall Street analysts Medlive Technology Co., Ltd.’s price is currently Undervalued.
Does Medlive Technology Co., Ltd. pay dividends?
Medlive Technology Co., Ltd. pays a Quarterly dividend of HK$0.163 which represents an annual dividend yield of 2.72%. See more information on Medlive Technology Co., Ltd. dividends here
What is Medlive Technology Co., Ltd.’s EPS estimate?
Medlive Technology Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Medlive Technology Co., Ltd. have?
Medlive Technology Co., Ltd. has 740,114,140 shares outstanding.
What happened to Medlive Technology Co., Ltd.’s price movement after its last earnings report?
Medlive Technology Co., Ltd. reported an EPS of HK$0.267 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -3.646%.
Which hedge fund is a major shareholder of Medlive Technology Co., Ltd.?
Currently, no hedge funds are holding shares in HK:2192
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Medlive Technology Co., Ltd. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
35.05%
12-Months-Change
Fundamentals
Return on Equity
6.89%
Trailing 12-Months
Asset Growth
5.66%
Trailing 12-Months
Company Description
Medlive Technology Co., Ltd.
Medlive Technology Co., Ltd., along with its affiliated entities, manages a digital platform tailored for medical professionals, serving both the Chinese mainland and international markets. Through its comprehensive platform, the company delivers a precision marketing and corporate solution encompassing a wide array of services. These include project oversight, clinical supervision, handling of clinical data, biostatistical analysis, drafting of study protocols, medical supervision, patient enrollment, and system support. Furthermore, it offers digital market intelligence, electronic data collection, real-world evidence generation, and the development of application software. Medlive also provides a medical knowledge solution focused on continuing medical education and tools for clinical decision-making, which involves licensing specialized software to physicians and other registered users, including various healthcare practitioners and pharmaceutical corporations. An intelligent patient management solution is another core offering, delivering chronic disease management services that cover online consultations, prescription fulfillment, and patient care facilitated by an Internet hospital. Additionally, it provides condition-specific patient education, involving the creation of content, development of specialized software, and associated support services. Originally established in 1996 as Kingyee Co., Limited, the enterprise adopted the name Medlive Technology Co., Ltd. in 2021. Its corporate headquarters are located in Beijing, China.
2192 Stock 12 Month Forecast
Average Price Target
HK$13.10
▲(33.27% Upside)
Technical Analysis
China Health Group
―
Shanghai Pharmaceuticals Holding Co
―
Sinopharm Group Co
―
IVD Medical Holding Limited
―
Charmacy Pharmaceutical Co., Ltd. Class H
―
Options Prices
Currently, No data available
---